Please assess the completion status of the following clinical trial:

Trial Title: Dose-Finding Study of Vadadustat in Japanese Subjects With Anemia Secondary to Dialysis-Dependent Chronic Kidney Disease (DD-CKD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female Japanese participants ≥20 years of age~* Receiving chronic maintenance hemodialysis for end-stage kidney disease~* Hemoglobin (Hb) \<10.0 grams per deciliter (g/dL)~Exclusion Criteria:~* Anemia due to a cause other than chronic kidney disease (CKD) or presence of active bleeding or recent blood loss~* Sickle cell disease, myelodysplastic syndromes, bone marrow fibrosis, hematologic malignancy, myeloma, hemolytic anemia, thalassemia, or pure red cell aplasia~* Red blood cell transfusion within 4 weeks prior to or during screening~* Anticipated to recover adequate kidney function to no longer require hemodialysis during study participation

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vadadustat, Dose 1 (Type: EXPERIMENTAL): Daily oral dose
- Vadadustat, Dose 2 (Type: EXPERIMENTAL): Daily oral dose
- Vadadustat, Dose 3 (Type: EXPERIMENTAL): Daily oral dose
- Placebo (Type: PLACEBO_COMPARATOR): Daily oral dose

Based on this trial design, predict the completion outcome and termination type (if applicable).